As the U.S. stock market reaches record highs amid an election-fueled rally, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, often seen as a ...

Fintel reports that on November 4, 2024, Oppenheimer downgraded their outlook for ESSA Pharma (NasdaqCM:EPIX) from Outperform ...

Fintel reports that on November 1, 2024, Jones Trading downgraded their outlook for ESSA Pharma (NasdaqCM:EPIX) from Buy to ...

US clinical-stage firm ESSA Pharma has made the decision to terminate the Phase II clinical trial evaluating in a 2:1 ...

ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over ...

Such findings raised questions about the added benefit of masofaniten, leading ESSA to abandon the drug’s development. In light of these results, Piper Sandler removed any projected value for ...

ESSA Pharma (EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer treatment. The trial tested masofaniten with enz ...

The company’s fifty day simple moving average is $5.59 and its two-hundred day simple moving average is $5.55. ESSA Pharma has a 52 week low of $1.40 and a 52 week high of $11.67. The stock has a ...

Piper Sandler analyst Joseph Catanzaro downgraded the rating on ESSA Pharma (EPIX – Research Report) to a Hold today, setting a price ...

In a report released on November 1, Maury Raycroft from Jefferies downgraded ESSA Pharma (EPIX – Research Report) to a Hold, with a price ...

Investing.com -- ESSA Pharma (NASDAQ:EPIX), a biotechnology company focused on developing treatments for metastatic castration-resistant prostate cancer, saw its stock downgraded by major ...

Essa Pharma’s sole clinical-stage candidate was on track to fall short against Xtandi in a phase 2 prostate cancer trial, ...